POLE/POLD1 mutation and tumor immunotherapy

J Exp Clin Cancer Res. 2022 Jul 2;41(1):216. doi: 10.1186/s13046-022-02422-1.

Abstract

POLE and POLD1 encode the catalytic and proofreading subunits of DNA polymerase ε and polymerase δ, and play important roles in DNA replication and proofreading. POLE/POLD1 exonuclease domain mutations lead to loss of proofreading function, which causes the accumulation of mutant genes in cells. POLE/POLD1 mutations are not only closely related to tumor formation, but are also a potential molecular marker for predicting the efficacy of immunotherapy in pan-carcinomatous species. The association of POLE/POLD1 mutation, ultra-high mutation load, and good prognosis have recently become the focus of clinical research. This article reviews the function of POLE/POLD1, its relationship with deficient mismatch repair/high microsatellite instability, and the role of POLE/POLD1 mutation in the occurrence and development of various tumors.

Keywords: Immune checkpoint inhibitor; MSI; POLD1; POLE; Tumor; Tumor mutation burden.

Publication types

  • Review

MeSH terms

  • DNA Polymerase II* / genetics
  • DNA Polymerase II* / metabolism
  • DNA Polymerase III* / genetics
  • DNA Polymerase III* / metabolism
  • Humans
  • Immunotherapy* / methods
  • Mutation
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Poly-ADP-Ribose Binding Proteins / genetics

Substances

  • Poly-ADP-Ribose Binding Proteins
  • POLD1 protein, human
  • DNA Polymerase II
  • DNA Polymerase III